Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/362 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME09001835
PMID: | 9001835
LR: | 20061115
CED: | 19970408
DCO: | 19970408
Autoren: | Talent JM; Gracy RW
Titel: | Pilot study of oral polymeric N-acetyl-D-glucosamine as a potential treatment for patients with osteoarthritis.
Quelle: | Clinical therapeutics; VOL: 18 (6); p. 1184-90 /1996 Nov-Dec/
PM: | Print
SU: | IM
Sprache: | English
CY: | UNITED STATES
JID: | 7706726
ISSN: | 0149-2918
CO: | CLTHDG
Institution: | Department of Biochemistry and Molecular Biology, University of North Texas Health Science Center, Fort Worth, USA.
DT: | Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Schlagwörter
CT: | ABSORPTION; ACETYLGLUCOSAMINE/pharmacokinetics; ACETYLGLUCOSAMINE/*therapeutic use; ADMINISTRATION, ORAL; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; FEMALE; FOLLOW-UP STUDIES; GLUCOSAMINE/pharmacokinetics; GLUCOSAMINE/therapeutic use; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS/blood; OSTEOARTHRITIS/*drug therapy; PILOT PROJECTS; POLYMERS/pharmacokinetics; POLYMERS/therapeutic use; REFERENCE VALUES; TREATMENT OUTCOME
CTG: | ABSORPTION; ACETYLGLUCOSAMIN/Pharmakokinetik; ACETYLGLUCOSAMIN/*therapeutische Anwendung; APPLIKATION, ORALE; ERWACHSENER; CHROMATOGRAPHIE, HOCHDRUCK-FLÜSSIGKEITS-; CROSS-OVER-STUDIEN; WEIBLICH; VERLAUFSSTUDIEN; GLUCOSAMIN/Pharmakokinetik; GLUCOSAMIN/therapeutische Anwendung; HALBWERTZEIT; MENSCH; MÄNNLICH; MENSCHEN IM MITTLEREN LEBENSALTER; OSTEOARTHROSE/Blut; OSTEOARTHROSE/*Arzneimitteltherapie; PILOTPROJEKTE; POLYMERE/Pharmakokinetik; POLYMERE/therapeutische Anwendung; REFERENZWERTE; BEHANDLUNGSERGEBNIS
TE: | Polymers; Glucosamine/3416-24-8; Acetylglucosamine/7512-17-6
CR: | 3416-24-8; 7512-17-6
AB: | Glucosamine and its derivatives, such as glucosamine sulfate and N-acetyl-D-glucosamine (NAG), have been shown to be effective in the treatment of patients with osteoarthritis. Unfortunately, the half-life of glucosamine in the blood is relatively short; therefore, a sustained-release form of the compound would be highly desirable. The purpose of this pilot study was to determine whether the polymeric form of NAG (POLY-Nag) could provide a longer-lasting oral source of NAG. Ten healthy subjects each ingested 1 g/d of either NAG or POLY-Nag for 3 days. After a 4-day washout period, each subject was crossed over to receive the other compound for 3 days. Serum samples were collected and analyzed using high-performance liquid chromatography. Results show that orally ingested NAG and POLY-Nag are absorbed, resulting in increased serum levels of NAG, and POLY-Nag appears to be at least as effective as NAG. Serum levels of NAG had decreased by 48 hours after cessation of ingestion of NAG or POLY-Nag but were still above baseline levels. Increases in serum glucosamine levels indicate that NAG and POLY-Nag are converted to glucosamine in vivo. In conclusion, POLY-Nag may provide a source of serum glucosamine for treatment of patients with osteoarthritis. Longer and more rigorous pharmaco-kinetic and clinical studies need to be done.

» Volltext »
» Fenster schließen »